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A B S T R A C T
Mesalamine (5-ASA) is widely used for the treatment of ulcerative colitis, a remitting condition
characterized by chronic inﬂammation of the colon. Knowledge about the molecular and cellular targets
of 5-ASA is limited and a clear understanding of its activity in intestinal homeostasis and interference
with neoplastic progression is lacking. We sought to identify molecular pathways interfered by 5-ASA,
using CRC cell lines with different genetic background. Microarray was performed for gene expression
proﬁle of 5-ASA-treated and untreated cells (HCT116 and HT29). Filtering and analysis of data identiﬁed
three oncogenic pathways interfered by 5-ASA: MAPK/ERK pathway, cell adhesion and b-catenin/Wnt
signaling. PAK1 emerged as a consensus target of 5-ASA, orchestrating these pathways. We further
investigated the effect of 5-ASA on cell adhesion. 5-ASA increased cell adhesion which was measured by
cell adhesion assay and transcellular-resistance measurement. Moreover, 5-ASA treatment restored
membranous expression of adhesion molecules E-cadherin and b-catenin. Role of PAK1 as a mediator of
mesalamine activity was validated in vitro and in vivo. Inhibition of PAK1 by RNA interference also
increased cell adhesion. PAK1 expression was elevated in APCmin polyps and 5-ASA treatment reduced its
expression. Our data demonstrates novel pharmacological mechanism of mesalamine in modulation of
cell adhesion and role of PAK1 in APCmin polyposis. We propose that inhibition of PAK1 expression by
5-ASA can impede with neoplastic progression in colorectal carcinogenesis. The mechanism of PAK1
inhibition and induction of membranous translocation of adhesion proteins by 5-ASA might be
independent of its known anti-inﬂammatory action.
 2012 Elsevier Inc. 
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Ulcerative colitis (UC) is a chronic inﬂammatory disease of the
rectum that may extend to more proximal parts of the colon in a
continuous fashion. Histopathology shows an inﬁltrate of neu-
trophils within the lamina propria and within mucosal cryptsAbbreviations: CRC, colorectal cancer; IBD, inﬂammatory bowel diseases; UC,
ulcerative colitis; AJ, adherens junction; PAK1, p21 activated kinase 1.
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Open access under CC BY-NC-ND license.leading to epithelial destruction [1]. The primary cause(s) of UC is
unknown, however, genetic and environmental factors are
involved [2]. Patients with UC are at risk of developing colorectal
cancer (CRC). Colon carcinogenesis involves multiple mutations or
epigenetic modiﬁcations followed by changes in gene expression.
These changes require several years leaving open a window of
opportunity to prevent the transition from normal to malignant
cells.
Sulfasalazine, a drug used in the treatment of chronic gut
inﬂammation, was developed to combine antibacterial and anti-
inﬂammatory effects [3]. The anti-inﬂammatory potential of its
metabolite mesalamine (5-amino salicylic acid, 5-ASA), has been
investigated in studies involving the arachidonic acid cascade,
cyclooxygenase and lipoxygenase metabolites [4,5]. Although,the
therapeutic efﬁcacy of mesalamine in inducing and maintaining
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associated carcinogenesis remains controversial [6,7]. Some
authors have found inhibitory effects on the growth of colorectal
cancer cells and in b-catenin signaling [8].
At the cellular level, 5-ASA reduces oxidative stress [9], inhibits
cell cycle progression through activation of a replication
checkpoint [10], decreases transcriptional activity of NF-kB
[11] while activating PPAR-gamma [12] and interfering with
the canonical Wnt pathway [13,14]. Though several potential
mechanisms of its action have been investigated, a clear
understanding of its interference with cancer development is
lacking [8]. Such understanding may help to identify key
regulators of colon homeostasis and carcinogenesis. To this
end, we identiﬁed both known (Wnt-b-catenin) and novel (cell
adhesion and MAPK/ERK) cellular mechanisms regulated by
mesalamine using differential gene expression analysis. PAK1
(p21-activated kinase-1) turned out to be the consensus target of
5-ASA, orchestrating all three pathways. In this study we
investigated the functional relevance of PAK1 as a mediator of
mesalamine activity in vitro and in vivo.
2. Materials and methods
2.1. Cell lines and reagents
Human colorectal carcinoma cell lines HCT116, HT29 (obtained
from ATCC) were grown in IMDM (Gibco/Invitrogen, Lofer, Austria)
containing 10% fetal bovine serum (FBS; Biochrom, Berlin,
Germany). 5-ASA (>99.9% pure; a generous gift from Shire Inc.,
Eysins, Switzerland) was dissolved in the culture medium (pH
adjusted to 7.2 with NaOH) as described earlier [10]. IPA3 (Sigma–
Aldrich) was dissolved in DMSO.
2.2. Microarray and data analysis
Accession number: The data is open to public at Array Express:
http://www.ebi.ac.uk/microarray-as/ae/; experiment ID E-TABM-
768
Total RNA was linearly ampliﬁed and ﬂuorescently labeled
using modiﬁed protocol of Low RNA Input Linear Ampliﬁcation Kit
(Agilent Technologies). The modiﬁcations to the protocol allow for
incorporation of aminoallyl-UTP (Epicenter Biotechnologies) into
ampliﬁed RNA and subsequent labeling by coupling with DY-547
NHS-ester and DY-647 NHS-ester ﬂuorescent dyes (Dyomics).
Fluorescently labeled cRNA from control and treated cells were
co-hybridized to Human OneArray oligonucleotide microarrays
(Phalanx Biotech). Four hybridizations in two replicas were
carried out for each time interval (8 and 24 h) for CRC cell lines
HCT116 and HT29. Microarrays were scanned with confocal
microarray scanner (ScanArray Express, Perkin Elmer), extraction
of spot intensities was done using QuantArray software (Packard
Biochip). Data was further processed (normalization, ﬁltering) in
R statistical environment (http://www.R-project.org) and R
Bioconductor [15] and analyzed with MEV software. Signiﬁcantly
up- and down-regulated genes were determined with SAM
algorithm implemented in MEV (DFCI, JCVI, and the University
of Washington). Gene expressions that were not different
between 8 and 24 h were selected to represent the change
induced by the treatment (5-ASA, 20 mM) in both the cell lines.
Analysis of microarray data was performed using various
available programs, including Pathway Studio Ariadne software
(Ariadne, Rockville, MD, http://www.ariadnegenomics.com), On-
to-Compare (Intelligent Systems and Bioinformatics Laboratory,
Wayne State University, http://vortex.cs.wayne.edu), and MAPP-
Finder (Gladstone Institutes, University of California, http://
www.genmapp.org/and http://www.gladstone.ucsf.edu).2.3. Cell fractionation, Western blotting and antibodies
Cytosolic and membrane fractions were collected as described
elsewhere [16]. Brieﬂy, cells were grown in 15 cm dishes and were
collected with 400 ml cold hypotonic buffer (10 mM Tris–HCl pH
7.5, 0.2 mM MgCl2, with protease and phosphatase inhibitors
(Roche) with a cell scraper. The extract was dounce homogenized
and kept on ice for 30 min. The extract was spun at 15,000  g for
45 min at 4 8C, and the supernatant was collected as the cytosolic
fraction. The pellet was washed twice in hypotonic buffer and then
resuspended by vortexing in 50 ml lysis buffer (150 mM NaCl,
20 mM Tris–HCl pH 7.5, 1% Triton X-100, and proteinase
inhibitors). The extract was vortexed for 10 seconds every
10 min and kept on ice for 30 min. Afterwards, the supernatant
was collected as the membrane fraction. Both fractions were
incubated with Laemmli sample buffer containing 10%
b-mercaptoethanol at 95 8C for 10 min and then analyzed by
western blot. Protein concentrations were measured by Bradford
assay (Bio-Rad). Proteins were separated by SDS-PAGE and
immunoblotted onto a PVDF membrane. The protein bands were
visualized with anti-rabbit or anti-mouse antibodies coupled to
horseradish peroxidase using the ECL kit (Amersham) or with
IRDye coupled antibodies (either or both mouse/rabbit; LI-COR)
and scanned on Odyssey imager (LI-COR Biotechnology). Primary
antibodies used were as follows: monoclonal antibody, anti-E-
cadherin, anti-b-catenin (BD Transduction Laboratories), Rad 6
(Zymed), pan-actin, calnexin, Lamin B1 (Santa Cruz Biotech),
FRZB, alpha-tubulin, anti-Oct1, Anti-Fibrillarin (Abcam), phos-
pho-b-catenin, PAK1, Na,K-ATPase, Phospho-p44/42 MAPK, and
p44/42 MAPK (Cell signaling).
2.4. Cell adhesion assay
Cell adhesion assay was modiﬁed and performed as described
previously [17,18]. Cells were treated with 5-ASA for 24 h
(5–20 mM; as indicated in ﬁgures), washed in PBS, counted and
plated equally (40–50,000 cells/well) in 24-well plates for
attachment. After 30 min of incubation, each plate was washed
with PBS until no ﬂoating cells remained and then replaced with
the fresh medium (without 5-ASA) and MTT reagent. This
washing step is critical for the cell attachment assay. After 4 h,
medium was removed and the remaining precipitates were
dissolved in DMSO/ethanol mixture (50/50, v/v). The experiment
was repeated three times, and for each condition, four wells
were scored.
2.5. Transcellular resistance measurement
Real time quantitative technique electric cell-substrate
impedance sensing (ECIS) was utilized for measuring cell
attachment [18]. The 96 well ECIS plate (Applied Biophysics,
96W10E+) was pre-coated with ﬁbronectin (10 mg/ml; Sigma,
F2006-1MG) for 1 h at 37 8C in a CO2 Incubator with 5% CO2.
Then 80,000 Caco-2 cells (Sigma, 86010202) per well were
plated in 200 ml Dulbeco‘s modiﬁed Eagle Medium (DMEM, 1%
L-Glutamine, 1% Penicillin/Streptomycin, 10% FCS; PAA, E15-
009) and incubated overnight. On the next day the plate was
connected with the ECISz instrument (Applied Biophysics) and
measured with an AC current of 4 kHz. The substances: control
(DMEM), 5-ASA 1 mM and 5 mM were pre- incubated in the
37 8C Incubator with 5% CO2 for 1 h in a 96well plate. Then the
experiment was paused and after removal of the old medium
the substances were added to the Caco-2 cells. ECIS plate was re-
connected with the instrument and the measurement was
continued. Afterwards the impedance (ohm) was normalized by
setting the time point 0 h at 1.
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Cells were ﬁxed in methanol and immunostaining was
performed using antibodies against b-catenin (clone 14/BD
Transduction Laboratories) and E-cadherin (clone 36/BD Trans-
duction Laboratories). For protein visualization AlexaFluor 488
and 568 antibodies (Invitrogen) were used. Nuclear staining was
performed using Vectashield with DAPI (Vector laboratories) for
mounting. Images were scanned at 40 magniﬁcation on a LSM
510 (Zeiss). Digital images were processed with Zeiss LSM
Browser.
2.7. Luciferase reporter assay
HT29 or HCT116 cells seeded in 6-well plates at 5  105 cells/
well were transfected with 2 mg of the TCF reporter pTOPFLASH
or pFOPFLASH (gift of Dr. Paiva, Yale University) and co-
transfected with 30 ng of pCMV-Renilla luciferase (Promega,
Madison, WI, USA) per well using Lipofectamine 2000 reagent
(Invitrogen Life Technologies) for 6 h. Cells were then treated
with 5-ASA (20 mM) for 8 h and 24 h and corresponding cell
lysates were subjected to dual luciferase reporter assay (Roche).
Fluorescence of luciferase levels was measured on a lumin-
ometer (Bio-Rad Laboratories).
2.8. Chromatin Immunoprecipitation (ChIP) assay
Cells were treated with 20 mM of 5-ASA for 24 h, washed and
ﬁxed with 1% formaldehyde. b-catenin immunopellets were then
separated onto chromatin DNA and protein fractions. Chromatin
in formaldehyde-ﬁxed cell lysates was sonicated to an average
size of 500 bp. Cell lysates were clariﬁed by centrifugation at
20,800  g for 10 min at 4 8C and incubated with primary antibody
overnight at 4 8C. Secondary rabbit anti-mouse IgG was then
added for 6 h. Immunocomplexes were captured with BSA/
glycogen-blocked protein A Sepharose (Calbiochem), washed,
and the bead pellet was resuspended in 100 ml of TE (pH 8.0). RNA
was digested for 30 min at 37 8C with 50 mg of RNase A (Roche).
SDS was added to 0.25% and proteins were digested with 250 mg of
proteinase K (Roche) for 12 h at 37 8C. Formaldehyde cross-links
were reversed at 65 8C for 6 h. Samples were phenol/chloroform-
extracted, and the DNA was precipitated in 100% ethanol. Samples
were corrected for input DNA and values obtained were
normalized to IgG control. DNA fraction was subjected to semi-
quantitative PCR with primers speciﬁc for the human c-Myc,
c-Net, Cdx1 and Cyclin D1 promoter regions and selected from
qPrimerDepot database. GoTaq Hot Start DNA polymerase
(Promega; 2.5 U/100 ml reactions) was used in 1x Green Flexi
buffer/2 mM MgCl2 (Promega). CHIP reactions were performed
using negative control IgG and RNA pol II antibody and GAPDH
control primers (ChIP-IT Control Kit-Human, Active Motif).
2.9. RNA interference
For PAK1 siRNA transfection, cells (HCT116 and HT 29) were
plated at a density of 1  105 cells per well in a six-well plate
and were transfected using 50 nM and 100 nM of PAK1 siRNA
duplex (dose was selected after titrating 10–100 nM duplex
RNA) with siRNA transfection reagent (Santa Cruz). Fresh
medium was added 24 h after transfection. Adhesion assay
was performed 48 h post transfection. siRNA oligonucleotides
were purchased from Dharmacon (catalog number D-003521-
03, Accession Numbers: NM_002576, target sequence CAU-
CAAAUAUCACUAAGUC). Control siRNA-A: sc-37007 (Santa Cruz
Biotechnology, CA) was prepared based on the manufactures
instructions.2.10. Animals and experimental procedure
Animal studies were performed under the Austrian Animal
Experiments Regulation and approved by the animal experiment
committee in accordance with the institutional good scientiﬁc
practice guidelines. 4–6 week old heterozygous female and male
C57BL/6J-ApcMin/+ mice (Jackson Laboratories) were fed with
either 2500 mg/kg 5-ASA (A3537, Sigma–Aldrich) mixed into the
chow or with a control diet (C1000, Altromin). The 5-ASA dose
corresponds to the intake of 3 g/day in humans. After 12 weeks the
mice were euthanized, the whole gut dissected and coiled up to a
Swiss-roll. The intestine was ﬁxed in neutral buffered formalin
(10%) for 24 h and embedded in parafﬁn. Serial tissue cuts (4 mm)
were H&E stained and analyzed histopathologically by a blinded
pathologist. Tumors were counted regarding size (small < 0.3 mm,
medium < 1 mm, large polyp >1 mm).
2.11. Immunohistochemistry
Immunohistochemistry analysis was done on parafﬁn-em-
bedded mouse intestine. Brieﬂy, slides were dried, de-waxed in
xylol and rehydrated using a decreasing alcohol series. After
blocking of endogenous peroxidase with 15% H202 in Methanol,
antigen retrieval was performed in 10 mM citrate buffer, pH 6.
Subsequently slides were blocked in 2% horse serum, 3% BSA in
Tris-buffer and endogenous IgG was blocked with Vector M.O.M.
Blocking Reagent. Staining was performed using Avidin–biotin
complex method. Brieﬂy, antibody against PAK1 (#2602, Cell
signaling) or E-cadherin (clone 36/BD Transduction Laboratories)
or c-Myc (9E10 abcam; 1:1000 dilution) was incubated 4 8C
(overnight), followed by incubation with biotinylated anti-
mouse/rabbit antibody and avidin–biotin-HRP complex. Staining
was visualized using DAB and nuclear counterstaining was
performed using hematoxylin. Slides were dehydrated and
embedded in Histoﬂuid. A four grade scoring system as described
previously (18) was used for scoring immunoreactivity (0/1/2/3/x
where x = 25 and % cells with no staining= 0; 1 = weak;
2 = moderate; 3 = strong; with maximum reactivity score or
IRS = 12). Averaged IRS score of two independent investigators
was used for the analysis. APCmin sections were evaluated from
ﬁve untreated and ﬁve 5-ASA treated mice. For all antibodies used,
staining with only secondary antibody was also performed to rule
out nonspeciﬁc binding.
2.12. Statistical analysis
All in vitro experiments were independently performed three
times each. Statistical analysis was performed by ANOVA
(including linear contrasts for trend analysis). Post hoc analysis
was performed by independent t-test provided that global ANOVA
test was statistically signiﬁcant. p value < 0.05 was considered
signiﬁcant. SPSS software (version 17) was used for all analyses.
3. Results
3.1. 5-ASA interferes with multiple signaling pathways
Differential gene expression was tested in colorectal cell lines
(HT29 and HCT116) treated with 20 mM 5-ASA (8 and 24 h) as
described in the methods. These cell lines were selected for their
complementary differences in gene mutations like p53, b-catenin
and APC [19,20]. Microarray data was further normalized, ﬁltered
and analyzed with MEV software. Almost 300 up- or down-
regulated genes were selected (http://www.ebi.ac.uk/arrayex-
press/; experiment ID E-TABM-768; some of the genes differen-
tially regulated by 5-ASA are listed in Table 1). Clustering was
Table 1
5-ASA regulated genes and their tumorigenic properties.
Gene name Function Folds difference
Rad6 DNA damage and repair protein that is overexpressed in many cancers;
transcriptional target of the TCF/b-catenin pathway
1.85
PAK1 Increased Pak-1 expression was shown in malignant progression of human
colorectal carcinoma. It interferes with Wnt/b-catenin,MAPK pathway, cell
migration and adhesion.
2.1
RAN (ras-related nuclear protein) Regulator of Wnt signaling, possibly involved in colorectal carcinogenesis. 2.7
DAAM1 (disheveled associated
activator of morphogenesis 1)
DAAM1 mediates transduction of disheveled-dependent WNT/PCP signals to the
RhoA signaling cascade and interferes with JNK signaling pathway through
MAPKKKs and MAPKK4/7. It regulates cell morphogenesis and actin dynamics
through Rho GTPases and Src.
1.65
DKK1 DKK1, extracellular Wnt inhibitor, is transcriptionally silenced by
hypermethylation in colon cancer cell lines. Restoration of DKK-1 function reduces
colony formation and tumor growth inhibition.
1.55
Sox9 Strong SOX9 expression was shown to be an independent adverse prognosticator in
colorectal cancer. In CRC cells SOX9 inhibits overexpression of carcinoembrionic
antigen that protects cells against apoptosis and contributes to carcinogenesis.
1.7
FRZB (frizzled-related protein B) The loss of FrzB in gastric cancer suggests that it acts as a tumor suppressor. Lost of
FRZB function or gene polymorphism may contribute to in the development of
colorectal cancer.
2.1
WNT9A WNT protein member that plays a role in carcinogenesis. Depletion of WNT9A
increases cell proliferation. WNT9A promoter methylation and decreased gene
expression occurs frequently in primary colon cancers and acute lymphoid
leukemias.
2.2
NFAT5 (nuclear factor of activated T-cells) NGAT5 belongs to a NFAT family of transcription factors that exhibit strong anti-
tumor-promoting activity.
+2.2
ITGA1 (adhesion molecule integrin a 1) Member of the integrin family, has been linked with epithelial cell motility, cellular
survival and carcinoma invasion, hallmarks of metastatic tumors. It expression
correlates with the NFAT activity. This protein heterodimerizes with the beta 1
integrin subunit to form a cell-surface receptor for collagen and laminin. The
heterodimeric receptor is involved in cell–cell adhesion and may play a role in
inﬂammation and ﬁbrosis.
+1.6
Dusp4 Downregulation of Dusp26 contributes to malignant phenotypes of glioma. +1.5
PAI-1-RBP (plasminogen activator inhibitor-1
mRNA binding protein)
PAI-1 belongs to a family of factors associated with the invasion of gastric cancer
cells through the basement membrane.
1.9
Lamin B Lamins are upstream regulators of an actin dynamics pathway that contribute to
the loss of cell adhesion, leading to enhanced cell motility and consequently
increased invasive potential within certain tumors.
2.0
KIF5B KIFs, microtubule-directed motor proteins that participate in subcellular transport
of several cancer-related proteins, including the ß-catenin-cadherin(s) complex
and APC. Dusp26 is a regulator of the KIF3.
1.84
GLY1 (1 N-glycanase 1) GLY1 modiﬁes E-cadherin within a complex of N-glycans. Removal of this complex
increases interaction of E-cadherin-b-catenin complexes with actin cytoskeleton
and destabilizes adherens junctions (AJs).
1.6
CALM1 (Calmodulin 1) Member of calcium-modulated proteins that functions in growth and cell cycle as
well as in signal transduction and the synthesis and release of neurotransmitters.
Calmodulin and dependent protein phosphatises are overexpressed in many
tumors.
1.8
KLK10 (kallikrein 10) KLK10 expression is up-regulated in CRC and GC and higher expression of KLK10
closely correlates with advanced disease stage, which predicts a poorer prognosis.
2.0
BCLAF1 (BCL2-associated transcription factor 1) It binds to DNA in vitro and represses transcription. Overexpression of Bclaf1 was
shown to result in apoptosis and transcriptional repression.
1.7
BAG1 (BCL2-associated athanogene) Predominantly expressed in colon carcinoma tissues, related to the malignant
degree, inﬁltration and metastasis of colon carcinoma.
1.6
MAP2K1IP1 Part of a MAPK scaffold complex that modulates the Raf-MKK1/2-ERK1/2 pathway.
Upregulated during cancer progression.
1.5
RAB18 Encodes antigen that was found preferentially in cancer patients. 1.95
PPP2CA Encodes Raf-mediated protein from MAPK cascade, overexpressed in cancers. 1.85
PROHIBITIN (PHB) Encodes mitochondrial protein that activates Raf/MEK/ERK pathway by active Ras
and is therefore involved in cancer pathways. It modulates epithelial cell adhesion
and migration. PHB directly interacts with C-Raf. In PHB silenced cells, the adherent
junctions are stabilized.
1.9
ELK4 One of the Ets transcription factors implicated in various aspects of tumor
progression.
1.4
NRAS (neuroblastoma RAS viral (v-ras)
oncogene homolog)
N-Ras(G12D), RAS homolog, confers resistance to apoptosis. 1.75
RAP2A RAS family member regulates androgen sensitivity in human prostate cancer cells
by antagonizing PSA expression. Plays a role in cell migration and adhesion.
1.7
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subjected to bio-computational pathway analysis (as described in
Section 2) that revealed involvement of genes in three pathways:
canonical Wnt signaling (Fig. 1a), Ras/MAP kinase (Fig. 1b) and cell
adhesion (Fig. 1c). Validation of selected 5-ASA targets wasconﬁrmed by Western blotting (Fig. 1d). Out of these three
signaling pathways interfered by 5-ASA, Wnt/b-catenin has been
previously investigated [13,14]. In our experiments, western blot
with MAPK antibodies conﬁrmed downregulation of this pathway
by 5-ASA in HCT116 and HT29 (data not shown). However, it
Fig. 1. Differential regulation of genes by 5-ASA. Two cell lines (HCT116, HT29) treated with 20 mM 5-ASA (8, 24 h) were used in the analysis. The graphs represent expression
of genes representative of the three major pathways obtained after microarray data analyses as described in methods. (a) Wnt/b-catenin (b) MAPK signaling (c) Cell adhesion.
(d) Validation of some targets by Western blot. 5-ASA inhibited PAK1 that mediates all three pathways. Pan-actin was used as a loading control.
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adhesion. The analysis did not provide any clear mechanism. We
further investigated the effect of 5-ASA on cell adhesion and its
underlying mechanism.
3.2. 5-ASA increases intercellular cell adhesion
Cell adhesion was increased in both HT29 and HCT116 cells
upon treatment with 5-ASA (Fig. 2a). Statistical analysis revealed
that observed increase in the cell adhesion was less pronounced in
HT29 compared to HCT116. Interestingly, this effect was not
speciﬁc to colon epithelial cells as treatment with 5-ASA also
proved to enhance cell adhesiveness in HeLa cells. Increase in cell
adhesion was observed only by 5-ASA and not its inactive
metabolite N-acetyl-5-ASA (data not shown).
Electric cell-substrate impedance sensing (ECIS) technology is
a sensitive technique to monitor and quantify cell adhesion and
barrier function of cell monolayer [21]. We measured impedance
upon 5-ASA treatment on Caco-2 cells which have been
successfully utilized for such assays [22]. An increase in
impedance with time was observed upon 5-ASA treatment
(Fig. 2b). Low doses of 5-ASA were used in this assay, as cells
must proliferate to form a monolayer, and 5-ASA is shown to
cause cell cycle arrest in a dose dependent manner [10]. The
measurements were taken at low frequency as it respondsstrongly to the changes between the cells. Therefore, an increase
in intercellular resistance is an indirect measurement of stronger
cell-to-cell contacts. This data demonstrated that 5-ASA activity
increased intercellular cell adhesion.
3.3. 5-ASA induces membranous expression of E-cadherin and
b-catenin
Anchoring cellular junctions that lead to adhesion can occur at
the point of cell-to-cell contact (AJs, adherens junctions; desmo-
somes) or cell-to-matrix contact (focal adhesions). In epithelia, the
AJ protein complex consists of E-cadherin that directly interacts
with p120 catenin and b-catenin, which in turn binds alpha-
catenin [23]. Moreover, cadherins also interfere with the Wnt/b-
catenin pathway by sequestering b-catenin and promoting cell
adhesion [24]. This led us to examine E-cadherin expression and
localization upon 5-ASA treatment. Western blot analysis was
performed on the whole cell extract and membrane fractions.
Interestingly, E-cadherin expression remained unchanged in
whole cell extracts in the presence of 5-ASA treatment (Fig. 3a).
This indicated that 5-ASA activity is unlikely to alter its de novo
synthesis. However, we observed an increase in membranous
E-cadherin (Fig. 3a) in both cell lines examined. This effect was
more pronounced in HCT116 cells. Immunoﬂuorescent staining
showed that untreated cells expressed less E-cadherin on the cell
Fig. 2. 5-ASA increases cell adhesion. (a) Adhesion of HCT116 and HT29 upon 5-ASA
treatment (20 mM; 24 h). The graph is representative of one of the three
independent experiments, SD of quadruplicate samples. Statistical analysis
revealed that 5-ASA increases cell adhesion in a dose-dependent manner (p = 0.005
for the linear contrast). This effect was more pronounced in HCT116 cells. (b) Electric
cell substrate impedance sensing (ECIS) assay to monitor cell adhesion upon 5-ASA
treatment. The graph shows an increase in impedance upon 5-ASA treatment. The cell
attachment data was collected using AC current at 4000 Hz.
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at cell-to-cell contacts or AJs (Fig. 3b). As was observed with
western blotting, the effect was more prominent in HCT116 cells
compared to HT29. This observation was consistent with the
previous observation in cell adhesion assay.
As b-catenin directly interacts with E-cadherin in forming AJs,
we also examined the expression and membranous localization of
b-catenin in 5-ASA treated cells. Western blot showed a similar
increase in the membranous fraction of b-catenin as previously
observed with E-cadherin (Fig. 3a). Immunoﬂuorescent staining of
b-catenin demonstrated its localization at AJs in 5-ASA treated
cells (Fig. 3c).
We also assessed nuclear and cytoplasmic expression levels of
b-catenin and phospho-b-catenin (at N-terminal serine33/37
and threonine 41) in HCT116 and HT29 cells. Upon treatment with
5-ASA, a decrease in nuclear b-catenin and an increased
phosphorylation of b-catenin in both nuclear and cytoplasmic
fractions was observed (Fig. 3d). To further examine, whether
b-catenin localization at AJs was associated with the decrease in
nuclear Wnt/b-catenin signaling through TCF, we performed a
b-catenin/TCF induced transactivation assay using a reporter
plasmid (pTOPFlash or pFOPFlash). 5-ASA treatment suppressed
transcription of the reporter in both HT29 and HCT116 cells
(Fig. 3e). We performed chromatin-immunoprecipitation, for
5-ASA-induced alterations in Wnt target genes by near veriﬁed
b-catenin/TCF binding elements. Reduced b-catenin binding at
the promoter region of Wnt/b-catenin target genes was seen for
c-Myc, c-Met, Cdx1 and Cyclin D1 (Fig. 3f). These ﬁndings support
the notion that 5-ASA inhibits b-catenin transcriptional activity,
modulates its N-terminal phosphorylation and promotes inter-
cellular cell adhesion through its membranous translocation.
Overall, these observations elucidated a novel role of 5-ASA in cell
adhesion through inhibition of b-catenin signaling and recruit-
ment of adhesion proteins at AJs.3.4. Depletion of PAK1 increases cell adhesion and membranous
localization of b-catenin and E-cadherin
In the three molecular pathways identiﬁed by microarray
analysis, PAK1, a serine/threonine kinase and a Rac/Cdc42 effector
protein, was found to be the common factor (Fig. 1). In colon
cancer, PAK1 expression levels are elevated [25,26]. Recently, a
direct interaction and phosphorylation of b-catenin by PAK1 was
shown to be required for full activation of canonical Wnt signaling
[25]. Taken together, these observations link PAK1 activity in both
MAPK signaling and the Wnt/b-catenin pathway disrupted by 5-
ASA. However, the role of PAK1 in 5-ASA mediated cell adhesion
was unclear. Treatment with 5-ASA inhibits expression of PAK1
(Fig. 1d). As localization and activation of PAK1 is critical in
regulating its function, we examined the effect of 5-ASA on PAK1
expression in cell fractions (Fig. 4a). Nuclear PAK1 is associated
with advanced stages of CRC [27] and we also observed high PAK1
expression in the nuclear fraction of untreated cells. 5-ASA
treatment reduced PAK1 expression in both the cytoplasm and
nucleus, with the effect more pronounced in the nuclear fraction.
To further verify if 5-ASA acts through inhibition of PAK1, we
assessed the effect of PAK1 depletion on cell adhesion. Using siRNA
against PAK1 (Fig. 4b), we observed an increase in the cell adhesion
in HCT116 and HT29 cells (Fig. 4c) similar to what was observed
upon 5-ASA treatment (Fig. 2a). Notably, compared to HT29,
HCT116 cells were more susceptible to PAK1 inhibition. HT29 is
mutated in APC and in the absence of evidence; it remains
speculative if APC mutation modulates PAK1 expression in these
cells. We also utilized a biochemical approach to inhibit PAK1
kinase activity by IPA3 [28]. As was observed with PAK1 silencing,
cell adhesion increased in a dose dependent manner in IPA3
treated cells (Fig. 4d). This observation substantiated that PAK1
interferes with cell adhesion in colon epithelial cells.
To determine, if silencing of PAK1 has similar molecular effects
like 5-ASA, we performed E-cadherin immunostaining in PAK1-
depleted cells (Fig. 4e). Increased membranous E-cadherin
conﬁrmed the functional role of PAK1 silencing in establishing
cell-to-cell contacts. Sub-cellular localization of b-catenin upon
PAK1 depletion was also examined using immunoﬂuorescence
microscopy. PAK1-depleted cells showed an increased membra-
nous expression of b-catenin at cellular junctions (Fig. 4e). The
effect of siPAK1 on membranous increase of E-cadherin and
b-catenin was also conﬁrmed by western blot (data not shown). A
similar membranous increase in E-cadherin and b-catenin was
observed in the HT29 cells transfected with siPAK1 (data not
shown). We observed that in siPAK1 cells, b-catenin expression
was reduced compared to control. This is consistent with its role
in inhibiting b-catenin activity [29]. An increased interaction of
E-cadherin and b-catenin at cell contacts was also observed in
PAK1 depleted cells. The data thus uncovered the functional role of
PAK1 inhibition by 5-ASA in cell adhesion.
Altogether, these results provide novel insights for 5-ASA
activity (through inhibition of PAK1) in E-cadherin trafﬁcking and
cell adhesion. We conclude that increased membranous expression
of junctional molecules (E-cadherin and b-catenin) by 5-ASA
contributes to intercellular adhesion, which could potentially
impede with neoplastic progression and restore epithelial integrity
in the context of UC.
3.5. In vivo effects of 5-ASA activity on PAK1 and E-cadherin
expression in APCmin mouse model
The immunoﬂuorescence data and western blot analysis in
PAK1-depleted cells indicated that inhibition of PAK1 (by siRNA or
5-ASA) was sufﬁcient for membranous accumulation of b-catenin
and E-cadherin. With emergence of PAK1 as a consensus target of
Fig. 3. 5-ASA recruits E-cadherin and b-catenin to the cell membrane. (a) Western blot analyses of E-cadherin and b-catenin in total (RIPA) or membrane fractions of 5-ASA
treated cells. The data is representative of three independent experiments (b) Immunoﬂuorescent detection of E-cadherin expression. Arrows indicate low levels of
membranous E-cadherin in untreated cells. (c) Immunoﬂuorescent detection of b-catenin. Arrows indicate AJs. Cells were grown on coverslips and treated with or without
5-ASA (20 mM) for 24 h. An increase in intercellular membranous E-cadherin and b-catenin was observed upon 5-ASA treatment. The experiment was performed three times.
(d) Protein proﬁles of cytoplasmic and nuclear b-catenin and phospho-b-catenin in cells treated with 5-ASA for indicated time intervals. (e) 5-ASA inhibits b-catenin
signaling in CRC cells. Luciferase reporter assay was performed in cells transfected with the TCF reporter pTOPFLASH or pFOPFLASH and co-transfected with pCMV-Renilla
luciferase. Following treatment with 5-ASA for 8 h and 24 h, luciferase was measured using a luminometer. All samples were taken in quadruplicates and independently
repeated 2 times (p < 0.05). (f) CHIP assay showing downregulation of transcriptional targets of b-catenin on 5-ASA treatment. Error bars represent SEM.
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(altered in CRC cells), our data suggests that 5-ASA counteracts
PAK1 activity in the colon. Inactivating mutations in the
adenomatous polyposis coli (APC) gene predispose to CRC by
constitutive activation of the b-catenin/Tcf complex [30]. Howev-
er, not all studies in literature agree with the efﬁcacy of 5-ASA in
reducing polyp formation in APCmin mouse model [31]. We
hypothesized that PAK1 contributes to b-catenin signaling in
APCmin mice and its inhibition by 5-ASA could interfere with
APCmin polyposis. We utilized this mouse model to test the
hypothesis. Analysis of polyp formation in the 5-ASA treated group
showed signiﬁcant reduction in polyp number (Fig. 5a). Immuno-
histochemistry was performed to examine PAK1 expression in the
polyps from control and 5-ASA treated mice. In the untreated
group, PAK1 expression was found to be enhanced in the tissuesections from APCmin polyps (Fig. 5b) and not in normal mucosa.
This observation indicated that PAK1 expression is modulated by
APCmin mutation and activated b-catenin signaling in the polyps.
5-ASA treatment of mice reduced PAK1 expression in such APCmin
polyps (Fig. 5b). Immunoreactive scores (IRS) of PAK1 staining
revealed a statistically signiﬁcant trend toward elevated PAK1
expression from normal mucosa through small polyps and large
polyps (Fig. 5c), emphasizing the role of PAK1 signaling in tumor
progression. Moreover, IRS revealed that 5-ASA treatment
signiﬁcantly reduced PAK1 expression, an effect that was more
pronounced in small polyps. This observation also suggests that,
inhibition of PAK1 by 5-ASA attenuates progression of neoplasia.
This was also reﬂected in the signiﬁcant reduction of number of
large polyps by 5-ASA (Fig. 5d). In control group, small polyps
proliferated further to become large polyps. 5-ASA treatment was
Fig. 4. PAK1 mediates 5-ASA effects. (a) Western blot showing inhibition of PAK1by 5-ASA in cytoplasmic and nuclear fractions. Fibrillarin and tubulin were used as control for
purity of cellular fractions. The blot represents one of the three independent experiments (b) Western blot to analyze PAK1 knockdown using siRNA. PAK1 depletion shows
decreased level of PAK1 protein upon increasing siRNA in CRC cells. (c) The effect of PAK1 depletion (by siRNA) on cell adhesion. Linear trend analysis by ANOVA revealed a
signiﬁcant dose-dependent effect on cell adhesion upon silencing PAK1 (p = 0.032) which was more pronounced in HCT116 cells. (d) The effect of IPA3 on cell adhesion. A dose
dependent increase in cell adhesion was observed upon pharmacological inhibition of PAK1 kinase activity. Linear trend analysis by ANOVA showed statistically signiﬁcant
dose dependence (p < 0.001) (e) PAK1 depletion increases membranous localization of E-cadherin and b-catenin. HCT116 cells stained with anti-E-cadherin or b-catenin
were analyzed by confocal microscopy. The experiment was repeated three times.
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impeding with tumor progression into large polyps. This was
reﬂected in the reduction of large polyps in 5-ASA treated group
and no signiﬁcant change in small polyps compared to untreated
controls. To conﬁrm the effect of 5-ASA in the reduction of
b-catenin/TCF signaling, we examined c-Myc (b-catenin target
gene) expression in these polyps. In control mice, c-Myc expression
was found to be highly elevated in all the polyps examined. The
difference between treated and control polyps was visible using
higher dilutions of c-Myc antibody. 5-ASA treatment signiﬁcantly
reduced nuclear c-Myc expression (Fig. 5e and f) indicating
inhibition of b-catenin transcriptional activity. Immunohisto-
chemical analysis was also performed for Ki-67 expression as a
marker of proliferation. There was no signiﬁcant difference
between the control and 5-ASA treated polyps (data not shown).
However, TUNEL staining revealed a signiﬁcant increase in
apoptosis in 5-ASA treated polyps compared to controls (data
not shown, separate manuscript). Mutations in tumor suppressor
gene APC stabilizes b-catenin and promotes its transcriptional
activity. We therefore propose that inactivated APC and activated
Wnt/b-catenin signaling stimulate PAK1 expression, which is
downregulated by 5-ASA activity.
We also performed E-cadherin and b-catenin immunostaining
in APCmin polyps in mice with and without 5-ASA in their diet. We
observed high expression of b-catenin in the polyps and nosigniﬁcant change was observed in the membranous expression
levels, in either of the groups (data not shown). Immunohis-
tochemistry analysis showed that E-cadherin expression was
hetrogenous in APCmin polyps (Fig. 5g). The effect of 5-ASA was
visible through induction of homogenous expression of E-cadherin
(Fig. 5g) along with enhanced membranous expression of
E-cadherin. E-cadherin is considered as a tumor suppressor gene
and this effect of 5-ASA might contribute to its chemopreventive
activity.
Taken together, the in vitro and in vivo data demonstrated a
novel activity of mesalamine, altering cellular signaling cascades
mediated by PAK1.
4. Discussion
Gene expression proﬁling in 5-ASA treated cells identiﬁed
three cellular signaling mechanisms (Fig. 1), some of which (Wnt/
b-catenin pathway) were recognized previously, others (cell
adhesion and ERK/MAP kinase pathways) emerged as novel targets
of 5-ASA. Cdc42/Rac1 effector molecule PAK1, was found to be the
common mediator of these pathways and hence, a consensus
target of 5-ASA. Cells treated with 5-ASA showed an increased
intercellular adhesion that was measured by ECIS. Overall, the data
demonstrated that 5-ASA increases cell adhesion; inhibits PAK1;
downregulates b-catenin signaling and promotes membranous
Fig. 5. Effect of 5-ASA in vivo. (a) Intestinal polyps per mouse in untreated and 5-ASA treated APCmin mice. The total number of polyps signiﬁcantly decreased upon treatment
with 5-ASA for 12 weeks. For statistical analysis the nonparametric Mann–Whitney and Wilcoxon test was performed to compare untreated vs 5-ASA treated group (b) PAK1
expression was elevated in APCmin polyps (left) and 5-ASA activity effectively reduced its expression (right). (c) Immunoreactivity score (IRS) of PAK1 expression in APCmin
polyps. Linear contrast analysis by ANOVA conﬁrmed that 5-ASA treatment signiﬁcantly reduced PAK1 expression (p = 0.015). This trend was most pronounced in small
polyps (p = 0.029) (d) Number of APCmin polyps separated for size. There was a signiﬁcant reduction in large polyps upon 5-ASA treatment. (e) Nuclear c-myc expression in
polyps from untreated and 5-ASA treated APCmin mice. Treatment with 5-ASA siginﬁcantly decreased nuclear c-myc staining within the polyps (p < 0.01). (f)Single polyp,
represented by a single dot in the plot (n = 16), were scored for nuclear c-myc expression within the polyp (0, no staining; 1, low staining intenstiy; 2, medium staining
instensity). Representative pictures were imaged at 200 magniﬁcation. (g) In APCmin polyps, E-cadherin was heterogeneously expressed in the epithelium that was distorted
in the architecture (left). 5-ASA treatment was effective in restoring homogeneity of E-cadherin expression as well as its membranous localization. This was also reﬂected in
re-organization of epithelial architecture (right). Image magniﬁcations 100.
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5-ASA activity were also mimicked by PAK1 inhibition and
demonstrated its role in cellular adhesion. This study shows novel
mechanism of 5-ASA activity in establishing cell-to-cell contacts,
which is critical for mucosal barrier integrity in the setting of
chronic gut inﬂammation and restoring epithelial homeostasis,
impeding carcinogenesis. In vivo data suggest a novel role of PAK1
in APCmin polyposis. 5-ASA counteracted polyp formation, possibly
through inhibition of PAK1. This study suggests that 5-ASA activity
may have wider implications in its therapeutic efﬁcacy, through
interference with cellular signaling that might be independent of
its anti-inﬂammatory action.
In the dynamic complex of AJ, the cytoplasmic domain of
E-cadherin forms a complex with b-catenin which is also shared
by canonical Wnt signaling pathway. Activation of Wnt/b-catenin
signaling is vital for gut homeostasis particularly for the
maintenance of intestinal crypt integrity. Activation of this
pathway inhibits cadherin-catenin mediated cell adhesion
through sequestration of b-catenin. Inhibition of b-catenin
signaling by 5-ASA was previously shown to be partially mediated
by upregulation of mu-protocadherin belonging to the cadherin
superfamily. In this study, mu-protocadherin was shown to
inhibit b-catenin signaling by sequestering it to the plasma
membrane [24]. Here, we show that 5-ASA facilitates recruitment
of both E-cadherin and b-catenin at cell-to-cell contacts with
consequential increase in intercellular adherence. Our ﬁndings
are also supported by another study that examined molecular
effects of 5-ASA in patients with sporadic colorectal adenomas
[32]. Besides downregulation of b-catenin signaling, the authors
found a signiﬁcant increase in E-cadherin membranous expres-
sion in the 5-ASA treated samples compared to placebo. These
observations emphasize the role of 5-ASA in establishing
intestinal architecture which is lost during chronic inﬂammation
and in neoplasia. The ambiguity of microarray data opened up
several possibilities of 5-ASA activity in cell adhesion and mucosal
healing. As we focused primarily on the mechanism of E-cadherin
and b-catenin regulation by 5-ASA, we cannot rule out the
potential involvement of other proteins implicated in epithelial
barrier function and mucosal integrity (such as tight junction
proteins, desmosomal proteins) that might be modulated by
5-ASA. Nevertheless, this study provides a ground to further
investigate the molecular mechanisms of 5-ASA in mucosal
healing in UC and in colorectal carcinogenesis.
As a molecular mediator, PAK1 regulates diverse cellular
mechanisms; it is critical in coordinating growth promoting
signaling pathways [24]; has been implicated in the regulation of
Wnt [25] and Ras signaling, and has a role in cytoskeleton
dynamics and cell motility [26]. Phosphorylation of MEK1 by
PAK1 in Ras-MAPK signal transduction is crucial [27]. We veriﬁed
the role of PAK1 as a mediator of 5-ASA activity in cell adhesion.
The data showed that inhibition of PAK1 (by siRNA) also resulted
in membranous localization of b-catenin and E-cadherin, as was
observed with 5-ASA. Previously, PAK1 was shown to contribute
in the destabilization of cell-to-cell contacts in keratinocytes [33].
Membranous translocation of b-catenin upon siPAK1 corrobo-
rates with ﬁndings by Zhu et al. (37). Their study demonstrated
PAK1 kinase activity contributes to nuclear localization and
signaling of b-catenin, whereas our data shows that inhibition of
PAK1 promotes b-catenin activity in cell adhesion at the
membrane. We also observed direct interaction of PAK1 and
b-catenin in colon epithelial cells (data not shown). Our in vivo
studies indicated that PAK1 activity is associated with APCmin
polyposis. Whether, the observed up-regulation of PAK1 in APC
mutant mice is a cause or consequence of activated b-catenin
signaling, needs further investigation. Additional mutations such
as KRAS are implicated in APC polyposis [34] which might activatePAK1. In our study, 5-ASA reduced number of APCmin polyps and
this corroborated with reduction in PAK1 expression that
increased with the size of polyps. We propose that PAK1 inhibition
by 5-ASA impedes with APCmin polyposis. We observed a
difference in the efﬁcacy of 5-ASA in reducing number of polyps
in APCmin mice compared to a previous report from Ritland et al.
[31]. This difference might be attributed to the drug concentra-
tions used. In this study 5-ASA corresponded to a dosage range of
100–1920 mg/kg/day and we used 2500 mg/kg (corresponding to
3 gram/day in humans). In recent years, PAK1 has been generating
interest as an oncogenic kinase [25,26,35] and attempts are in
progress to identify selective PAK1 inhibitors for cancer therapy
and its prevention [36,37]. Since, PAK1 emerged as a common
mediator linking cellular mechanisms disrupted by 5-ASA; it is
also likely to be an indirect target of 5-ASA. This study suggests the
regulation of E-cadherin/b-catenin/PAK1 axis by 5-ASA. PI3 K/Akt
signaling cooperates with Wnt/b-catenin signaling during
inﬂammation [38] and it is tempting to speculate that 5-ASA
regulates PAK1 through interference with this pathway. The
possibility that 5-ASA targets a molecule upstream of PAK1
responsible for its activation cannot be ruled out. Deregulation
and genetic association of Rac1 (Rho GTP-binding protein that can
activate PAK1) with UC has been recently identiﬁed [39]. Recent
studies provide evidence for association of PAK1 in sporadic colon
cancer and we propose that as a mediator of 5-ASA activity, it
contributes to colitis and inﬂammation driven colon cancer. We
are currently examining the regulation of PAK1 in UC and in
inﬂammation driven colon cancer. It remains to be investigated if
5-ASA acts through interference with either upstream activators
of PAK1 or other cellular signaling pathways, to validate if PAK1
can be used as a biomarker of 5-ASA activity.
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